Bernstein bets on this drugmaker for 28% upside citing a key value driver for the future
Shares of Zydus Lifesciences gained nearly 3% on Friday, September 18, after global brokerage Bernstein maintained its “Outperform” rating on the stock with a target price of ₹1,457 per share. The target price, the highest among all analysts tracking the drugmaker, implies an upside of more than 28% from Thursday’s closing price of ₹1,135.10. Novartis…
